Cbl (C14) Antibody-Delta Biolabs

Product Info
Background	The proto-oncogene c-Cbl was initially identified as the cellular homologue of v-Cbl oncogene that induces pre-B cell lymphomas and myeloid leukemias in mice (1&2). In more recent studies Cbl has been shown to be a negative regulator of tyrosine kinase signaling (2-4). The ubiquitin ligase activity of Cbl leads to the degradation of tyrosine kinases, thus attenuating the signal of receptors (3&4). Targets of Cbl include activated protein tyrosine kinases belonging to the Src and Syk/Zap-70 families (3). An additional mechanism to attenuate receptor signaling is thought to be achieved by Cbl?s interaction with downstream targets of tyrosine kinases, such as PI-3K and Vav (1&3).
Origin	Cbl (C14) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminal domain of human Cbl p120.
Product Details	Each vial contains 200 �g/ml of affinity purified rabbit IgG, Cbl (C14) DB068, in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
Competition Studies	A blocking peptide is also available, DB068P, for use in competition studies. Each vial contains 0.100 mg of peptide in 0.5 ml PBS with 0.1% sodium azide and 100 mg BSA.
Form	200 �g/ml rabbit polyclonal IgG in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
Immunogen	Synthetic peptide mapping to the carboxy terminal domain of human Cbl p120.
Specificity	Cbl (C14) is recommended to detect mouse, rat, and human Cbl.
Use	Western blotting, immunoprecipitation, and immunohistochemistry. Recommended western blotting starting dilution 1:200.
Storage	Store this product at 4� C, do not freeze. The product is stable for one year from the date of shipment.
References	1. Liu YC, Altman A. 1998. Cbl: complex formation and functional implications. Cell Signal 10(6):377-385. 2. Miyake S, Lupher ML, Andoniou CE, Lill NL, Ota S, Douillard P, Rao N, Band H. 1997. The Cbl protooncogen product: from an enigmatic oncogene to center stage of signal transduction. Crit Rev Oncog 8(2-3):189-218. 3. Rao N, Dodge I, Band H. 2002. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 71(5):753-763. 4. Sanjay A, Horne WC, Baron R. 2001. The Cbl family: ubiquitin ligases regulating signaling by tyrosine kinase. Sci STKE 2001(110):PE40.